Arch Plast Surg.  2012 Nov;39(6):585-592. 10.5999/aps.2012.39.6.585.

The Efficacy and Safety of Platelet-Rich Plasma and Adipose-Derived Stem Cells: An Update

• Choi J
• Minn KW
• Chang H

• KMID: 2120707
• DOI: http://doi.org/10.5999/aps.2012.39.6.585

Abstract

During the past decade, many studies using platelet-rich plasma (PRP) or adipose-derived stem cells (ASCs) have been conducted in various medical fields, from cardiovascular research to applications for corneal diseases. Nonetheless, there are several limitations of practical applications of PRP and ASCs. Most reports of PRP are anecdotal and few include controls to determine the specific role of PRP. There is little consensus regarding PRP production and characterization. Some have reported the development of an antibody to bovine thrombin, which was the initiator of platelet activation. In the case of ASCs, good manufacturing practices are needed for the production of clinical-grade human stem cells, and in vitro expansion of ASCs requires approval of the Korea Food and Drug Administration, such that considerable expense and time are required. Additionally, some have reported that ASCs could have a potential risk of transformation to malignant cells. Therefore, the authors tried to investigate the latest research on the efficacy and safety of PRP and ASCs and report on the current state and regulation of these stem cell-based therapies.

Keyword

Mesenchymal stem cells; Platelet-rich plasma; Treatment outcome; Safety

MeSH Terms

Consensus
Corneal Diseases
Humans
Korea
Mesenchymal Stromal Cells
Platelet Activation
Platelet-Rich Plasma
Stem Cells
Thrombin
Treatment Outcome
United States Food and Drug Administration
Thrombin